Tumor volumes between the sequential treatment groups were not significantly different; however, the final tumor volume in the anti-PD-1 → cisplatin group was lower than that in the isotype group and higher than in the concomitant group (Fig. 2B). This evidence concerns the gene PDCD1 and neoplasm.